Hanmi targets European market with Amosartan

Published: 2010-08-25 06:57:00

Updated: 2010-08-25 06:57:00

Hanmi Pharm said on August 23 it is conducting a phase I clinical trial of Amosartan (amlodipine camsylate+losartan potassium), a hypertension combination drug in CCB + ARB class, to obtain an approval in EU.

Company officials said that if the clinical study is deemed successful, Amosartan wil...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK